Sen. Amy Klobuchar (D-MN) announced on February 10, 2019 that she was running for the Democratic Party’s 2020 presidential nomination and dropped out on March 2, 2020.
The former prosecutor has not been especially outspoken about marijuana, but her support for certain reform legislation has earned her a “B” grade from NORML. Here’s more on where she stands on the issue.
This piece was last updated on March 2, 2020 to include the candidate’s statements and policy actions on marijuana since joining the race. It will continue to be updated on a rolling basis.
Legislation And Policy Actions
Klobuchar hasn’t introduced any cannabis bills herself, but she has signed onto a handful of pieces of marijuana legislation that her colleagues have filed.
In the 116th Congress, she cosponsored legislation to protect banks that service state-legal cannabis businesses from being penalized by federal regulators and a bill to expand research into marijuana and its constituents.
She’s a cosponsor of the Strengthening the Tenth Amendment Through Entrusting States (STATES) Act, which would amend the Controlled Substance Act to exempt states that have legalized cannabis from federal intervention. That bill was sponsored by presidential rival Sen. Elizabeth Warren (D-MA).
The former prosecutor also put her name on measures designed to expand research into marijuana by increasing the number of facilities permitted to cultivate cannabis for research purposes and require relevant federal agencies to reassess whether cannabidiol (CBD) should remain a controlled substance. Another proposal she cosponsored would remove CBD and “CBD-rich plants” from the definition of marijuana under federal law.
Unlike most of her Senate colleagues who are running for president in 2020, however, Klobuchar has not signed onto the far-reaching Marijuana Justice Act that Sen. Cory Booker (D-NJ) filed to deschedule cannabis and withhold funding from states with discriminatory enforcement.
But she is one of eight senators who signed a letter addressed to then-Attorney General Jeff Sessions, demanding answers about the status of applications to become federally authorized marijuana manufacturers for research purposes.
On The Campaign Trail
Klobuchar was asked at a presidential debate in February whether she felt a plan by rival candidate Sen. Bernie Sanders (I-VT) to immediately legalize marijuana and expunge prior convictions was realistic.
“It is realistic to want to legalize marijuana. I want to do that too,” she said. “I also think you need to look back at people’s records. You maybe can’t do that on day one, as he said. I think you want a process that you go through because there are too many people that have things on their records that stopped them from getting jobs.”
At an earlier debate, she was pressed on her record as a prosecutor as it concerns drug-related offenses. The senator said she oversaw “one of the most successful drug courts in the country.”
During a town hall event in February, the senator was asked by a voter about racial disparities in marijuana arrests and whether she would pardon people convicted of cannabis charges or move to expunge their records.
“Yes I would,” she said, before pivoting to rather awkwardly discuss Nevada’s current cannabis laws.
“By the way I’m well aware of what this state has done, in Nevada, where you legalized marijuana and where you actually put in place, I think, medical marijuana,” she said. “And you did that when you made some changes to the legislature and the new governor and the like, and so I think it’s really important to look at it as a way of making changes to our drug policy and doing the right thing. And I think that there’s other things we should be doing as well.”
CNN’s Anderson Cooper followed up to press Klobuchar on racial disparities that persisted in the criminal justice system during her time as a prosecutor.
“Anyone who’s worked in the criminal justice system knows there’s institutional racism,” she said, arguing that overall incarceration of African Americans went down 12 percent during her tenure.
“I have supported legalization federally,” Klobuchar said at a town hall event in New Hampshire in November 2019. “Yes, I’ve made that clear.”
Previous Quotes And Social Media Posts
Unlike many of her Democratic colleagues who are entering the 2020 race, Klobuchar rarely talks about cannabis in public. And a search of her Twitter and Facebook accounts turns up zero posts containing “marijuana,” though she did tweet approvingly about the Farm Bill’s inclusion of hemp legalization.
At the ag committee for the farm bill markup! Good safety net for farmers, nutrition and conservation programs…and hemp is in! Mitch McConnell joined markup today and said the bill will go to the floor before 4th of July…(When the corn is knee high)
— Amy Klobuchar (@amyklobuchar) June 13, 2018
Her Senate website contains just one mention of marijuana policy:
“Finally, I have opposed efforts to roll back the Obama Administration policy that the federal government would not interfere with state laws legalizing marijuana, and I cosponsored the STATES Act, bipartisan legislation introduced by Senators Elizabeth Warren and Cory Gardner to protect the ability of states to regulate marijuana,” she said. “I have also cosponsored legislation to make it easier for researchers to study the medical effectiveness and safety of marijuana and cannabidiol, which is used to treat conditions such as epilepsy.”
According to the Internet Archive, an earlier version of that page included a statement expressing support for her home state of Minnesota’s medical cannabis program.
“I support Minnesota’s medical marijuana law for people with cancer, multiple sclerosis, and other approved conditions,” the now-deleted section read just days before she launched her presidential campaign.
“I support the legalization of marijuana and believe that states should have the right to determine the best approach to marijuana within their borders,” Klobuchar told the Washington Post in a statement.
UPDATE from @amyklobuchar: “I support the legalization of marijuana and believe that states should have the right to determine the best approach to marijuana within their borders.” https://t.co/MxAi9XOUwz
— Jacqueline Alemany (@JaxAlemany) February 22, 2019
The support for ending prohibition is a shift from when, in a 1998 debate for Hennepin County attorney, she said, “I am opposed to the legalization of marijuana. I believe when you look at across the world what’s been happening people have realized that legalizing drugs is not the answer.”
As a senator in 2016, Klobuchar questioned a panel of researchers about marijuana, asking whether any particular legal states should serve as a model for others to follow and how to facilitate research into cannabis.
Klobuchar has dedicated several statements to “synthetic marijuana,” which advocates generally regard as a misnomer that conflates natural cannabis with dangerous synthetic chemicals.
Personal Experience With Marijuana
In January 2020, Klobuchar was asked by VICE News when was the last time she smoked marijuana.
“You have to go back to college days,” she said.
Marijuana Under A Klobuchar Presidency
Klobuchar hasn’t signaled strong support for marijuana legalization and her relative silence on the issue indicates that reform would not be an administrative priority if she were elected. However, she hasn’t expressed any support for federal intervention in local marijuana laws and has signed onto legislation to protect the right of states to regulate cannabis. For all intents and purposes, state-legal cannabis would likely be safe under Klobuchar, though she would probably put less political capital into pushing for a formal end to prohibition than other candidates might.
Congresswoman Voices Support For Allowing ‘Safe Supply’ Of Illegal Drugs For Harm Reduction
The freshman congresswoman says lawmakers should pursue providing people with a “safe supply” of drugs after decriminalization is enacted.
By Sessi Kuwabara Blanchard, Filter
Rep. Cori Bush (D-MO) has broken new ground by indicating her support for a safe supply of controlled substances for people who use them, in response to a Filter reporter’s question.
On Tuesday, the Drug Policy Alliance (DPA) held a press conference unveiling the Drug Policy Reform Act of 2021 (DPRA). It featured DPRA co-authors Bush and Rep. Bonnie Watson Coleman (D-NJ), together with DPA board member Dr. Mary Bassett and Neill Franklin, former executive director of Law Enforcement Action Partnership.
The bill will eliminate criminal penalties for possession of any scheduled substance up to quantities to be determined by a novel commission. It additionally invests in substance use disorder treatment and harm reduction services, while, among other things, preventing people being refused employment, housing, federal benefits and immigration status due to a criminal record for drug possession or personal drug use.
“Do we support a safe supply? Yes.”
During the press conference, DPA Executive Director Kassandra Frederique posed Filter’s question to the congresswomen: Do you support medical practitioners prescribing to patients their controlled substances of choice in order to encourage them to divest from the adulterated illicit supply, just as U.S. doctors did in the late 1910s and early 1920s?
Bush gave a clear answer. “Do we support a safe supply? Yes,” she said. She also explained why DPRA does not provide for some form of safe supply policy. “Right now, our focus is to decriminalize.”
Her comment appears to be one of the first, if not the first, public endorsements by a U.S. politician of a safe supply policy. It’s increasingly a priority for progressive drug-user activists in North America, driven by Canadian advocacy, like that of the Drug User Liberation Front.
“We are enthused to have a congressional leader who is willing to support evidence-based, life-saving interventions like safe supply,” Queen Adeyusi, a policy manager at DPA’s Office of National Affairs, told Filter.
Watson Coleman offered promising, albeit inconclusive, thoughts on the safe supply question. Part of the “whole issue of…personal use of substances,” she said, is “how you get them” and how consumers avoid “getting drugs that kill you as opposed to the right drug that you’re looking for.”
(Ensuring consumers have consistent easy access to pharmaceutical-grade drugs—instead of the unpredictable and adulterated illicit supply that’s driving fatal overdoses—has been shown in multiple studies to greatly reduce engagement with the unregulated supply.)
“To have it in the health care realm instead of the criminal realm is what we’re trying to accomplish,” said Watson Coleman.
“Everything that we’re talking about, we’re looking at it from an evidence-based standpoint,” said Bush. “So, making sure we are looking for guidance from people like Dr. Bassett and others.”
Watson Coleman suggested the question of safe supply policy could be one for the planned Commission on Substance Use, Health and Safety to consider, saying it “will be looking at issues of this nature and will be making recommendations to the secretary of Health and Human Services.”
According to a summary of DPRA published by DPA, the commission will provide “recommendations for preventing the prosecution of individuals possessing, distributing or dispensing personal use quantities of each drug for the purpose of subsistence distribution.”
The biggest win for the North American safe supply movement thus far has, according to advocates’ critiques, been largely symbolic: British Columbia’s mostly-unimplemented prescribing guidelines to provide consumers with pharmaceutical alternatives to adulterated street drugs.
A strong grassroots movement for safe supply policy has yet to materialize in the United States, and advocacy organizations like DPA are still developing their strategy. “We do deep work internally and with movement before moving to introduce legislation,” said Adeyusi. “We are working on a safe supply strategy with others, that can include legislation, but we are not ready yet.”
It appears that Bush may be a meaningful ally to such efforts when the time comes.
This article was originally published by Filter, an online magazine covering drug use, drug policy and human rights through a harm reduction lens. Follow Filter on Facebook or Twitter, or sign up for its newsletter.
Photo courtesy of Markus Spiske.
California Senator Previews Next Steps For Psychedelics Bill And Says It’s A Step Toward Decriminalizing All Drugs
A California senator sponsoring a bill to legalize possession of psychedelics in the state says the proposal is a step toward eventually decriminalizing all drugs.
“We want to get there,” he said in a recent meeting with activists and researchers, though he added that it’s possible the broader reform would need to be decided by voters.
Sen. Scott Wiener (D) made the comments last week in a chat hosted by the Psychedelic and Entheogen Academic Council (PEAC), discussing next steps for his psychedelics legislation after it passed in the Senate earlier this month. He said advancing the measure in the Assembly will be “very challenging” due to a number of factors, but he sees progress in the legislature.
It’s also unclear where Gov. Gavin Newsom (D) stands on the reform, he said—though the governor has long been an outspoken opponent of the war on drugs.
“This is the first time that this idea has ever been introduced in the legislature,” Wiener said. “It’s a brand new idea” that “many of my colleagues have never interacted with.”
The bill originally included record sealing and resentencing provisions for people previously convicted of psychedelics possession offenses, but that language was removed in its last committee stop prior to the Senate floor vote as part of an amendment from the sponsor.
Wiener said the reasoning behind that deletion was that the policy “ended up generating a huge price tag” based on a fiscal analysis, but it could be addressed in separate legislation if the main bill passes.
Since clearing the Senate, SB 519 has been referred to two Assembly committees—Public Safety and Health—but the clock is ticking to move it this session. The senator said it must be heard by the panels by July 15, and then it would go the the Appropriations Committee, which would need to take action by late August.
If all goes well, Wiener told the PEAC members that a floor vote in the Assembly would happen in early September. Should the chamber approve it, the bill would go back to the Senate for concurrence on any amendments (or otherwise go right to Newson’s desk). The governor would need to receive the bill by September 10, and then he would have 30 days to act on it.
Assembly passage is far from a given, however. There are “rivalries” and “tensions” between the two chambers, Wiener said, despite the fact that they’re controlled by the same party.
Colleagues in the same chamber might be more willing to “give you a benefit of the doubt in helping you move forward bills,” he said. What’s more, members in the Assembly go up for reelection more frequently than in the Senate, making them less inclined to back novel legislation like the psychedelics proposal.
The senator said one possible amendment that could be expected in the Assembly would be to remove ketamine from the list of psychedelics that would be included in the reform.
“There are disagreements within the psychedelic world on it,” he said. “It might come out. My view as you keep things in until you have to make a give, and that’s one that we could potentially give on. You don’t want to spontaneously give on things without getting some ability to move the bill forward as a result.”
Mescaline, a psychoactive compound derived from peyote and other cacti, is another controversial psychedelic.
It was specifically excluded from the bill’s reform provisions in peyote-derived form, but the possession of the compound would be allowed if it comes from other plants such as “the Bolivian Torch Cactus, San Pedro Cactus, or Peruvian Torch Cactus.”
That decision on the peyote exclusion was informed by native groups who have strongly pushed back against decriminalizing the cacti for conservationist reasons and because of its sacred value for their communities.
If enacted into law, the bill would remove criminal penalties for possessing or sharing numerous psychedelics—including psilocybin mushrooms, DMT, ibogaine, LSD and MDMA—for adults 21 and older.
Marijuana Moment is already tracking more than 1,100 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.
Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
The state Department of Public Health would be required to establish a working group “to study and make recommendations regarding possible regulatory systems that California could adopt to promote safe and equitable access to certain substances in permitted legal contexts.” Those recommendations would be due by January 1, 2024.
For psilocybin specifically, the legislation would repeal provisions in California statute that prohibit the cultivation or transportation of “any spores or mycelium capable of producing mushrooms or other material” that contain the psychoactive ingredient.
But this bill, Wiener emphasized at the beginning of the meeting, is ultimately an incremental step to ending the drug war.
“My view is we should be decriminalizing possession and use of all drugs—and we want to get there,” he said. “This is a step just like cannabis [legalization] was a step. And ultimately we may need to go to the voters for the broader drug decriminalization like Oregon.”
For the time being, however, the senator encouraged PEAC members in San Francisco, where lawmakers are more amenable to psychedelics reform, to reach out to people in other areas of the state to apply pressure on their representatives.
Meanwhile, a group of California activists announced plans earlier this year to put an initiative to legalize the use and retail sale of psilocybin on the state’s 2022 ballot. That group, Decriminalize California, said that it would first work to convince lawmakers to pursue reform and then take the issue directly to the people if the legislature fails to act.
The psychedelics effort in the California legislature, which Wiener first previewed back in November, comes as activists are stepping up the push to enact psychedelics reform locally in cities in the state and across the country. The bill notes those efforts in an explanation of the proposal.
The Northampton, Massachusetts City Council passed a resolution in April to deprioritize enforcement of laws against the possession, use and distribution of a wide range of psychedelics such as psilocybin and ayahuasca. It’s the third city in the state to advance the policy change, following Somerville and Cambridge.
These are some of the latest iterations of a national psychedelics reform movement that’s spread rapidly since Denver became the first city to decriminalize psilocybin mushrooms in 2019.
In Oregon, November’s election saw the passage of a historic initiatives to legalize psilocybin mushrooms for therapeutic purposes and more broadly decriminalize possession of all drugs.
The governor of Connecticut signed legislation last week that includes language requiring the state to carry out a study into the therapeutic potential of psilocybin mushrooms.
Texas lawmakers also recently sent their governor a bill to require the state study the medical benefits of psychedelics for military veterans.
A New York lawmaker introduced a bill this month that would require the state to establish an institute to similarly research the medical value of psychedelics.
In Oakland, the first city where a city council voted to broadly deprioritize criminalization of entheogenic substances, lawmakers approved a follow-up resolution in December that calls for the policy change to be adopted statewide and for local jurisdictions to be allowed to permit healing ceremonies where people could use psychedelics.
After Ann Arbor legislators passed a decriminalization resolution last year, a county prosecutor recently announced that his office will not be pursuing charges over possessing entheogenic plants and fungi—“regardless of the amount at issue.”
The Aspen, Colorado City Council discussed the therapeutic potential of psychedelics like psilocybin and proposals to decriminalize such substances at a meeting last month. But members said, as it stands, enacting a reform would be more better handled at the state level while entheogens remain strictly federally controlled.
Seattle lawmakers also recently sent a letter to members of a local task force focused on the opioid overdose epidemic, imploring the group to investigate the therapeutic potential of psychedelics like ayahuasca and ibogaine in curbing addiction.
Photo courtesy of Wikimedia/Mushroom Observer.
New Jersey Attorney General Cracks Down On ‘Gift’ Marijuana Schemes Involving Overpriced Snacks
The attorney general of New Jersey on Tuesday sent warning letters to companies that are effectively circumventing the state’s marijuana laws by “gifting” cannabis in exchange for non-marijuana-related purchases such as overpriced cookies, brownies and stickers.
Gifting is lawful between adults 21 and older under New Jersey’s adult-use cannabis law, but a number of businesses are allegedly taking advantage of that policy by giving away “free” cannabis products to those who purchase other items like snacks and baked goods.
No retail marijuana businesses have been licensed since the state enacted recreational legalization earlier this year, which followed voter approval of a reform initiative during the November 2020 election. Licensing regulations still need to be developed before adult-use shops can open.
Have you heard about businesses that “gift” marijuana w/ the purchase of snacks or other items? This isn’t the kind of cannabis business allowed by NJ’s new law. We’re warning these businesses to stop unlawful practices that could undercut the legal market.https://t.co/pYBODk12DY
— AG Gurbir Grewal (@NewJerseyOAG) June 15, 2021
“In legalizing adult-use cannabis in New Jersey, the Legislature made it clear they were creating a regulated market with restrictions on how that market operates,” Attorney General Gurbir Grewal said in a press release. “Instead of waiting for those regulations to be established, some vendors have decided to move forward on their own, in ways that the law does not allow.”
“Today we’re making it clear that we will not permit these entities to undermine the regulated cannabis marketplace the Legislature created or to compete unfairly with properly licensed cannabis businesses,” he said.
Four Sky High Munchies, Slumped Kitchen LLC, NJGreenDirect.com LLC and West Winds Wellness were targeted with cease and desist letters, which state that the cannabis gifts that they’re offering appear to be central to their business transactions. The non-cannabis items are generally overpriced, the press release notes.
New Jersey’s legalization law establishes the Cannabis Regulatory Commission (CRC) to oversee the market and create licensing rules. CRC Chairperson Dianna Houenou said that the division “is committed to establishing a safe marketplace of cannabis products.”
“Those trying to preempt the rules and transfer unregulated and untested marijuana items jeopardize public health and undermine confidence in the forthcoming regulated cannabis industry,” she said.
“We will not allow vendors to misrepresent what they’re selling,” Kaitlin Caruso, acting director of the state’s Division of Consumer Affairs, said. “Under our consumer protection laws, vendors are subject to fines and penalties for making false or misleading statements about what they’re selling. We have warned these companies about our concerns, and to stop conduct that could violate our laws.”
New Jersey’s attorney general has been proactive about cannabis reform implementation since the legalization bill was enacted.
The day after Gov. Phil Murphy (D) signed bills to legalize and decriminalize marijuana, Grewal directed prosecutors to drop cases for cannabis-related offenses and issued separate guidance for police on how to proceed under the updated laws.
The attorney general also encouraged prosecutorial discretion for marijuana cases in earlier memos prior to the bill’s signing.